Pharvaris BV (PHVS)

Name: Pharvaris BV (PHVS) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Pharvaris BV (PHVS)

Stock Card

$36.71

$-0.30 (-0.80%)

As on 27-Aug-2026 10:35EDT

Market cap

$2,546 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

7.3

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Pharvaris BV (PHVS) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 36.30 High: 37.49

52 Week Range

Low: 20.65 High: 38.13

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.7 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-1.4
Debt to Equity

--
Book Value

$--
EPS

$--
Face value

--
Shares outstanding

70,204,506

6 Years Aggregate

CFO

€-235.00 Mln

EBITDA

€-284.39 Mln

Net Profit

€-256.21 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Pharvaris BV (PHVS)	32.3	7.4	22.8	52.9	24.0	12.8	--
BSE Sensex	-9.1	1.1	1.2	-4.8	5.8	6.6	10.7
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 27-Aug-2026 | #As on 26-Oct-2023

Company	2025	2023	2022
Pharvaris BV (PHVS)	44.8	149.3	-21.8
S&P Small-Cap 600	4.0	13.9	-17.4
BSE Sensex	9.1	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Pharvaris BV (PHVS)	36.7	2,546.3	0.0	-171.6	--	-60	--	7.3
Affimed N.V. - ADR	0.1	3.0	0.9	-70.0	-7,823.0	-241.9	--	0.1
Centogene N.V. - ADR	0.1	9.4	48.5	-35.5	-117.5	397.6	--	0.9
CureVac NV (CVAC)	4.7	1,049.3	510.5	193.6	-21.7	25.5	7	1.0
InflaRx N.V. - ADR	2.4	309.5	0.0	-39.1	281,529.0	-41.7	--	1.8
LAVA Therapeutics NV (LVTX)	1.7	45.8	5.0	-23.3	-442.3	-121	--	3.6
ProQR Therapeutics N.V. - ADR	2.3	330.2	18.5	-42.3	-230.0	-65.7	--	3.5

Shareholding Pattern

View Details

About Pharvaris BV (PHVS)

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a... small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland. Read more

Co-Founder, CEO & Executive Director

Mr. Berndt Axel Edvard Modig CPA, M.B.A.
Co-Founder, CEO & Executive Director

Mr. Berndt Axel Edvard Modig CPA, M.B.A.
Headquarters

Zug
Website

https://pharvaris.com

FAQs for Pharvaris BV (PHVS)

What is the current share price of Pharvaris BV (PHVS) Today?

The share price of Pharvaris BV (PHVS) is $36.71 (NASDAQ) as of 27-Aug-2026 10:35 EDT. Pharvaris BV (PHVS) has given a return of 23.96% in the last 3 years.

What is the current PB & PE ratio of Pharvaris BV (PHVS)?

Since, TTM earnings of Pharvaris BV (PHVS) is negative, P/E ratio is not available.
The P/B ratio of Pharvaris BV (PHVS) is 7.34 times as on 21-Aug-2026, a 111 premium to its peers’ median range of 3.48 times.

PE & PB ratio at the end of financial year.